Clinical trials targeting the IL17 pathways show improvement in other inflammatory conditions, such as psoriasis, however, their administration has shown links to both new-onset and exacerbation of IBD, emphasizing the complexity and potential risks associated with manipulating this pathway in IBD therapy (62, 63). This evidence concerns the gene IL17A and psoriasis.